Novel nitric oxide donors are coronary vasodilators that also bind to the papain-like protease of SARS-CoV-2

Several investigational nitric oxide donors were originally created to correct vascular endothelial dysfunction in cardiovascular diseases. These 48 compounds contain an urea-like moiety attached to the well-known NO donors isosorbide 2- and 5-mononitrate. CR-0305 and CR-0202 were synthesized and fo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomedicine & pharmacotherapy 2024-04, Vol.173, p.116378-116378, Article 116378
Hauptverfasser: Schmedtje, John F., Ciske, Fred, Muzzarelli, Kendall M., Assar, Zahra
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 116378
container_issue
container_start_page 116378
container_title Biomedicine & pharmacotherapy
container_volume 173
creator Schmedtje, John F.
Ciske, Fred
Muzzarelli, Kendall M.
Assar, Zahra
description Several investigational nitric oxide donors were originally created to correct vascular endothelial dysfunction in cardiovascular diseases. These 48 compounds contain an urea-like moiety attached to the well-known NO donors isosorbide 2- and 5-mononitrate. CR-0305 and CR-0202 were synthesized and found to be nontoxic in the cell lines HMEC-1, A549/hACE2 and VeroE6. CR-0305 induced vasodilation in human coronary arteries ex vivo. Since NO can also have antiviral properties, a study of drug-protein interactions with SARS-CoV-2 was undertaken using in silico modeling. CR-0305 experimentally outperformed the other compounds, including CR-0202, in binding the catalytic site of SARS-CoV-2 papain-like protease (PLpro). PLpro is a primary target for therapeutic inhibition of SARS-CoV-2 as it mediates viral replication and modulates host innate immune responses. CR-0305 is predicted to sit firmly in the PLpro catalytic pocket as confirmed by molecular dynamics simulations, wherein stability of binding to the catalytic site of PLpro induces a conformational change in the BL2 loop to a more closed conformation as observed previously with GRL0617. Surface plasmon resonance was performed with CR-0305 and CR-0202 to characterize binding affinity to purified SARS-CoV-2 PLpro protein. CR-0305 and CR-0202 also inhibited SARS-CoV-2 infection compared to vehicle as measured by virus N protein staining with a specific antibody in A549-ACE2 and VeroE6 cells at 20 µM. CR-0305 is a coronary vasodilator that appears to bind to the catalytic site of the PLpro of SARS-CoV-2 while targeting delivery of antiviral NO to cells infected by SARS-CoV-2, suggesting multiple indications for future development. •The nitric oxide donor CR-0305, binds the catalytic site of SARS-CoV-2 papain-like protease.•PLpro is a primary target for therapeutic inhibition of SARS-CoV-2.•CR-0305 is a coronary vasodilator that may target delivery of NO to cells infected by SARS-CoV-2.
doi_str_mv 10.1016/j.biopha.2024.116378
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2958291432</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332224002622</els_id><sourcerecordid>2958291432</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-216fb220650cf604aa9c190b40814e60a7445021cd1bebec50c862077040aa213</originalsourceid><addsrcrecordid>eNp9kE1P4zAQhi0EgvLxDxDykUu64484yQUJVbCLhBZp-bhajjMRLmlcbLdi_z2uAnvcky3P83pmHkLOGcwZMPVjOW-dX7-aOQcu54wpUdV7ZMaaEgoFUO2TGVSlKITg_Igcx7gEgFKJ-pAciVo2XIpqRobffosDHV0KzlL_4TqknR99iNQEpNYHP5rwl25N9J0bTNpV0qtJ1AzR09aNHU0-vyBdm7VxYzG4t3wPPqGJSH1PH6__PBYL_1LwU3LQ5xiefZ0n5Pn25mnxq7h_-Hm3uL4vrCirVHCm-pZzUCXYXoE0prGsgVZCzSQqMJWUJXBmO9ZiizZjteJQVSDBGM7ECbmc_s1jvG8wJr1y0eIwmBH9JmrelDVvmBQ8o3JCbfAxBuz1OrhV3lgz0DvPeqknz3rnWU-ec-ziq8OmXWH3L_QtNgNXE4B5z63DoKN1OFrsXECbdOfd_zt8AgCuj1s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2958291432</pqid></control><display><type>article</type><title>Novel nitric oxide donors are coronary vasodilators that also bind to the papain-like protease of SARS-CoV-2</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Schmedtje, John F. ; Ciske, Fred ; Muzzarelli, Kendall M. ; Assar, Zahra</creator><creatorcontrib>Schmedtje, John F. ; Ciske, Fred ; Muzzarelli, Kendall M. ; Assar, Zahra</creatorcontrib><description>Several investigational nitric oxide donors were originally created to correct vascular endothelial dysfunction in cardiovascular diseases. These 48 compounds contain an urea-like moiety attached to the well-known NO donors isosorbide 2- and 5-mononitrate. CR-0305 and CR-0202 were synthesized and found to be nontoxic in the cell lines HMEC-1, A549/hACE2 and VeroE6. CR-0305 induced vasodilation in human coronary arteries ex vivo. Since NO can also have antiviral properties, a study of drug-protein interactions with SARS-CoV-2 was undertaken using in silico modeling. CR-0305 experimentally outperformed the other compounds, including CR-0202, in binding the catalytic site of SARS-CoV-2 papain-like protease (PLpro). PLpro is a primary target for therapeutic inhibition of SARS-CoV-2 as it mediates viral replication and modulates host innate immune responses. CR-0305 is predicted to sit firmly in the PLpro catalytic pocket as confirmed by molecular dynamics simulations, wherein stability of binding to the catalytic site of PLpro induces a conformational change in the BL2 loop to a more closed conformation as observed previously with GRL0617. Surface plasmon resonance was performed with CR-0305 and CR-0202 to characterize binding affinity to purified SARS-CoV-2 PLpro protein. CR-0305 and CR-0202 also inhibited SARS-CoV-2 infection compared to vehicle as measured by virus N protein staining with a specific antibody in A549-ACE2 and VeroE6 cells at 20 µM. CR-0305 is a coronary vasodilator that appears to bind to the catalytic site of the PLpro of SARS-CoV-2 while targeting delivery of antiviral NO to cells infected by SARS-CoV-2, suggesting multiple indications for future development. •The nitric oxide donor CR-0305, binds the catalytic site of SARS-CoV-2 papain-like protease.•PLpro is a primary target for therapeutic inhibition of SARS-CoV-2.•CR-0305 is a coronary vasodilator that may target delivery of NO to cells infected by SARS-CoV-2.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2024.116378</identifier><identifier>PMID: 38492437</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Antiviral Agents - pharmacology ; Coronary Artery ; COVID-19 ; Humans ; Hypoxia ; Molecular Docking Simulation ; Nitric Oxide ; Nitric Oxide Donors - pharmacology ; Papain ; Papain-Like Protease ; Peptide Hydrolases ; Pharmaceuticals ; Protease Inhibitors ; SARS-CoV-2 ; Vasodilator Agents ; Vasodilators</subject><ispartof>Biomedicine &amp; pharmacotherapy, 2024-04, Vol.173, p.116378-116378, Article 116378</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c357t-216fb220650cf604aa9c190b40814e60a7445021cd1bebec50c862077040aa213</cites><orcidid>0000-0001-6008-6203 ; 0000-0002-1022-8557</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biopha.2024.116378$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38492437$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schmedtje, John F.</creatorcontrib><creatorcontrib>Ciske, Fred</creatorcontrib><creatorcontrib>Muzzarelli, Kendall M.</creatorcontrib><creatorcontrib>Assar, Zahra</creatorcontrib><title>Novel nitric oxide donors are coronary vasodilators that also bind to the papain-like protease of SARS-CoV-2</title><title>Biomedicine &amp; pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>Several investigational nitric oxide donors were originally created to correct vascular endothelial dysfunction in cardiovascular diseases. These 48 compounds contain an urea-like moiety attached to the well-known NO donors isosorbide 2- and 5-mononitrate. CR-0305 and CR-0202 were synthesized and found to be nontoxic in the cell lines HMEC-1, A549/hACE2 and VeroE6. CR-0305 induced vasodilation in human coronary arteries ex vivo. Since NO can also have antiviral properties, a study of drug-protein interactions with SARS-CoV-2 was undertaken using in silico modeling. CR-0305 experimentally outperformed the other compounds, including CR-0202, in binding the catalytic site of SARS-CoV-2 papain-like protease (PLpro). PLpro is a primary target for therapeutic inhibition of SARS-CoV-2 as it mediates viral replication and modulates host innate immune responses. CR-0305 is predicted to sit firmly in the PLpro catalytic pocket as confirmed by molecular dynamics simulations, wherein stability of binding to the catalytic site of PLpro induces a conformational change in the BL2 loop to a more closed conformation as observed previously with GRL0617. Surface plasmon resonance was performed with CR-0305 and CR-0202 to characterize binding affinity to purified SARS-CoV-2 PLpro protein. CR-0305 and CR-0202 also inhibited SARS-CoV-2 infection compared to vehicle as measured by virus N protein staining with a specific antibody in A549-ACE2 and VeroE6 cells at 20 µM. CR-0305 is a coronary vasodilator that appears to bind to the catalytic site of the PLpro of SARS-CoV-2 while targeting delivery of antiviral NO to cells infected by SARS-CoV-2, suggesting multiple indications for future development. •The nitric oxide donor CR-0305, binds the catalytic site of SARS-CoV-2 papain-like protease.•PLpro is a primary target for therapeutic inhibition of SARS-CoV-2.•CR-0305 is a coronary vasodilator that may target delivery of NO to cells infected by SARS-CoV-2.</description><subject>Antiviral Agents - pharmacology</subject><subject>Coronary Artery</subject><subject>COVID-19</subject><subject>Humans</subject><subject>Hypoxia</subject><subject>Molecular Docking Simulation</subject><subject>Nitric Oxide</subject><subject>Nitric Oxide Donors - pharmacology</subject><subject>Papain</subject><subject>Papain-Like Protease</subject><subject>Peptide Hydrolases</subject><subject>Pharmaceuticals</subject><subject>Protease Inhibitors</subject><subject>SARS-CoV-2</subject><subject>Vasodilator Agents</subject><subject>Vasodilators</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1P4zAQhi0EgvLxDxDykUu64484yQUJVbCLhBZp-bhajjMRLmlcbLdi_z2uAnvcky3P83pmHkLOGcwZMPVjOW-dX7-aOQcu54wpUdV7ZMaaEgoFUO2TGVSlKITg_Igcx7gEgFKJ-pAciVo2XIpqRobffosDHV0KzlL_4TqknR99iNQEpNYHP5rwl25N9J0bTNpV0qtJ1AzR09aNHU0-vyBdm7VxYzG4t3wPPqGJSH1PH6__PBYL_1LwU3LQ5xiefZ0n5Pn25mnxq7h_-Hm3uL4vrCirVHCm-pZzUCXYXoE0prGsgVZCzSQqMJWUJXBmO9ZiizZjteJQVSDBGM7ECbmc_s1jvG8wJr1y0eIwmBH9JmrelDVvmBQ8o3JCbfAxBuz1OrhV3lgz0DvPeqknz3rnWU-ec-ziq8OmXWH3L_QtNgNXE4B5z63DoKN1OFrsXECbdOfd_zt8AgCuj1s</recordid><startdate>202404</startdate><enddate>202404</enddate><creator>Schmedtje, John F.</creator><creator>Ciske, Fred</creator><creator>Muzzarelli, Kendall M.</creator><creator>Assar, Zahra</creator><general>Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6008-6203</orcidid><orcidid>https://orcid.org/0000-0002-1022-8557</orcidid></search><sort><creationdate>202404</creationdate><title>Novel nitric oxide donors are coronary vasodilators that also bind to the papain-like protease of SARS-CoV-2</title><author>Schmedtje, John F. ; Ciske, Fred ; Muzzarelli, Kendall M. ; Assar, Zahra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-216fb220650cf604aa9c190b40814e60a7445021cd1bebec50c862077040aa213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antiviral Agents - pharmacology</topic><topic>Coronary Artery</topic><topic>COVID-19</topic><topic>Humans</topic><topic>Hypoxia</topic><topic>Molecular Docking Simulation</topic><topic>Nitric Oxide</topic><topic>Nitric Oxide Donors - pharmacology</topic><topic>Papain</topic><topic>Papain-Like Protease</topic><topic>Peptide Hydrolases</topic><topic>Pharmaceuticals</topic><topic>Protease Inhibitors</topic><topic>SARS-CoV-2</topic><topic>Vasodilator Agents</topic><topic>Vasodilators</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schmedtje, John F.</creatorcontrib><creatorcontrib>Ciske, Fred</creatorcontrib><creatorcontrib>Muzzarelli, Kendall M.</creatorcontrib><creatorcontrib>Assar, Zahra</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine &amp; pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schmedtje, John F.</au><au>Ciske, Fred</au><au>Muzzarelli, Kendall M.</au><au>Assar, Zahra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel nitric oxide donors are coronary vasodilators that also bind to the papain-like protease of SARS-CoV-2</atitle><jtitle>Biomedicine &amp; pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2024-04</date><risdate>2024</risdate><volume>173</volume><spage>116378</spage><epage>116378</epage><pages>116378-116378</pages><artnum>116378</artnum><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>Several investigational nitric oxide donors were originally created to correct vascular endothelial dysfunction in cardiovascular diseases. These 48 compounds contain an urea-like moiety attached to the well-known NO donors isosorbide 2- and 5-mononitrate. CR-0305 and CR-0202 were synthesized and found to be nontoxic in the cell lines HMEC-1, A549/hACE2 and VeroE6. CR-0305 induced vasodilation in human coronary arteries ex vivo. Since NO can also have antiviral properties, a study of drug-protein interactions with SARS-CoV-2 was undertaken using in silico modeling. CR-0305 experimentally outperformed the other compounds, including CR-0202, in binding the catalytic site of SARS-CoV-2 papain-like protease (PLpro). PLpro is a primary target for therapeutic inhibition of SARS-CoV-2 as it mediates viral replication and modulates host innate immune responses. CR-0305 is predicted to sit firmly in the PLpro catalytic pocket as confirmed by molecular dynamics simulations, wherein stability of binding to the catalytic site of PLpro induces a conformational change in the BL2 loop to a more closed conformation as observed previously with GRL0617. Surface plasmon resonance was performed with CR-0305 and CR-0202 to characterize binding affinity to purified SARS-CoV-2 PLpro protein. CR-0305 and CR-0202 also inhibited SARS-CoV-2 infection compared to vehicle as measured by virus N protein staining with a specific antibody in A549-ACE2 and VeroE6 cells at 20 µM. CR-0305 is a coronary vasodilator that appears to bind to the catalytic site of the PLpro of SARS-CoV-2 while targeting delivery of antiviral NO to cells infected by SARS-CoV-2, suggesting multiple indications for future development. •The nitric oxide donor CR-0305, binds the catalytic site of SARS-CoV-2 papain-like protease.•PLpro is a primary target for therapeutic inhibition of SARS-CoV-2.•CR-0305 is a coronary vasodilator that may target delivery of NO to cells infected by SARS-CoV-2.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>38492437</pmid><doi>10.1016/j.biopha.2024.116378</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-6008-6203</orcidid><orcidid>https://orcid.org/0000-0002-1022-8557</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0753-3322
ispartof Biomedicine & pharmacotherapy, 2024-04, Vol.173, p.116378-116378, Article 116378
issn 0753-3322
1950-6007
language eng
recordid cdi_proquest_miscellaneous_2958291432
source MEDLINE; Elsevier ScienceDirect Journals Complete; EZB-FREE-00999 freely available EZB journals
subjects Antiviral Agents - pharmacology
Coronary Artery
COVID-19
Humans
Hypoxia
Molecular Docking Simulation
Nitric Oxide
Nitric Oxide Donors - pharmacology
Papain
Papain-Like Protease
Peptide Hydrolases
Pharmaceuticals
Protease Inhibitors
SARS-CoV-2
Vasodilator Agents
Vasodilators
title Novel nitric oxide donors are coronary vasodilators that also bind to the papain-like protease of SARS-CoV-2
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T05%3A01%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20nitric%20oxide%20donors%20are%20coronary%20vasodilators%20that%20also%20bind%20to%20the%20papain-like%20protease%20of%20SARS-CoV-2&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Schmedtje,%20John%20F.&rft.date=2024-04&rft.volume=173&rft.spage=116378&rft.epage=116378&rft.pages=116378-116378&rft.artnum=116378&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2024.116378&rft_dat=%3Cproquest_cross%3E2958291432%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2958291432&rft_id=info:pmid/38492437&rft_els_id=S0753332224002622&rfr_iscdi=true